Mission Statement

Health economics is a subject that applies economic theory, models and empirical techniques to the analysis of decision-making by individuals, health care providers and governments with respect to health and health care.

The aim of the new Department of Health Economics (DHE) is to support efficiency and equity concerning health and health care and create relevant interdisciplinary collaborations within the Medical University of Vienna and with other Austrian and international research and decisions making institutions by: 

  • Promoting the understanding and use of health economics in research and decision making nationally and internationally
  • Developing relevant undergraduate, graduate and professional education and training programmes in Austria
  • Fostering research capacity development through the supervision of master and doctorate students in health economics
  • Excelling in collaborative applied and methodological research programmes both nationally and internationally
  • Acting as a point of call for health care professionals for expert advice

Major research areas include the synthesis of evidence on and appraisal of the socioeconomic burden of diseases, the costs, benefits and cost-effectiveness of preventative, diagnostic and treatment interventions both alongside clinical studies and using modelling techniques. Further research interests cover the evaluation of health services and health systems.


» 16-18 October 2019: The DHE Short Course "Evidence-based healthcare evaluation" is taking place. For more information and registration: DHE Short Course

»29-31 March 2019: ICMPE Conference in Venice - Fourteenth Workshop on Costs and Assessment in Psychiatry: The Value of Mental Health Services 

  • Claudia Fischer: "Valuation Methods in Costing for International, Multi-Sectoral Mental Health Economic Evaluations: A Structured Scoping Review." (oral presentation)
  • Judit Simon: "Inter-sectoral Costs and Benefits of Mental Care in Europe: European Research Project PECUNIA."(oral presentation)
  • Dennis Wienand: "The Excess Costs and Resource Use of Physical Comorbidities in Patients with Mental Health Disorders: A Systematic Review.
  • Giulio Castelpietra, Judit Simon, Luis Salvador-Carulla: "Ambiguity in Psychotherapy Definition: Is There an Urgent Need of an International Classification?" (poster)

» 08 March 2019, TODAY: Judit Simon has been showcased in today´s EU H2020 programme News dedicated to inspirational women in science on International Women´s Day: https://twitter.com/EU_H2020/status/1103613824958164992

» March 2019: Timea Helter was awarded a software grant from Sawtooth Software to gain full access to their services. She is listed as one of the their grant recipients under: https://www.sawtoothsoftware.com/index.php?option=com_content&view=article&id=2074

» 1 March 2019: 4th ATHEA-conference in Vienna

  • Judit Simon: "Multi-sectoral costs and benefits in health economic evaluations across Europe: The PECUNIA project" (oral presentation)
  • Susanne Mayer: "Valuation methods in costing for international, multi-sectoral health economic evaluations: a structured scoping review" (oral presentation) 

» 20 February 2019: The Department of Health Economics, Center for Public Health, Medical University of Vienna is wishing to appoint a Departmental Administrator starting 1 April 2019. Closing date for applications: 12 March 2019, 4 pm. For detailed information please visit the DHE job section. 

» 11-12 February 2019: Judit Simon and Claudia Fischer participated in the Kick-Off meeting of the new EU-project "the iLIVE  project - Living well, dying well" in Rotterdam, the Netherlands.

» 2009 to 2015: Monitoring evidence on overall survival benefits of anti-cancer drugs approved by the European Medicines Agency between 2009-2015. N. Grössmann, M. Robausch, K. Rosian, C. Wild, J. Simon.

The introduction of fast-track licensing strategies increases the approval of anti-cancer drugs with ambiguous benefit-risk profiles. The objective of our study was to monitor these therapies and identify any post-approval updates on survival. Our findings indicate that there is a lack of knowledge on overall survival in one-third of oncology drugs after several years of approval. Therefore, systematic post-approval monitoring mechanisms of cancer drugs will be of high relevance.